Today's Rundown Another setback for AstraZeneca as lupus drug fails phase 3 test Arvinas lines up for $100M IPO Qiming, Hillhouse lead Jacobio’s $55M series C CRISPR halts muscle decline in dog model of DMD Lilly hands its oncology baton—and big ambitions—to R&D executive Anne White EuroBiotech Report—Affimed-Genentech, Genomics-Vertex, Harbour B round, Evotec and KaNDy FiercePharmaAsia—HKEX reality check; Zai Lab’s eczema flop; WuXi AppTec’s co-CEO Chutes & Ladders—Allergan architect bids farewell Featured Story | | | Friday, August 31, 2018 Despite encouraging midstage data for AstraZeneca’s drug for systemic lupus erythematosus, anifrolumab has missed the target in the first of two ongoing phase 3 trials, putting its future in doubt. |
|
|
Top Stories Thursday, August 30, 2018 Arvinas has filed to raise up to $100 million in its IPO, which will get its lead assets through the IND stage and into phase 1. Friday, August 31, 2018 China’s Jacobio Pharmaceuticals has raised $55 million to advance an oncology asset into the clinic, conduct preclinical work and ramp up its R&D pipelines. Thursday, August 30, 2018 A UT Southwestern team led by Eric Olson, founder of gene therapy company Exonics Therapeutics, is reporting that correcting a gene mutation responsible for some forms of Duchenne muscular dystrophy using CRISPR restored up to 92% of muscle function in dogs. Friday, August 31, 2018 With oncology head Sue Mahony retiring Friday, Eli Lilly has her replacement ready to step in. Anne White, currently VP of portfolio management for Lilly’s Chorus and next-generation R&D units, will take on the role of SVP and president of Lilly Oncology, a unit Lilly says will be key to its growth future. Thursday, August 30, 2018 In this week's EuroBiotech Report, Genentech and Affimed pen a cancer pact, Vertex teams up with Genomics, Harbour raises $85 million and more. Friday, August 31, 2018 Ascletis' stock price slip serves as a wake-up call for other prerevenue biotechs eyeing Hong Kong listing; Zai Lab's dermatitis therapy licensed from GSK fails in phase 2; WuXi AppTec promotes CFO to co-CEO; and more. Friday, August 31, 2018 An Allergan architect bids farewell as its board revamp continues; Gilead steals the commercial chief from Amgen; Roche Diagnostics' head plans to step down; and Editas loses its CMO. Those moves plus more hirings, firings and retirings throughout the industry. | This week's sponsor is ExL Events. | | Let’s talk about success: Technology transfer with a CMO partner | ExL's 5th Technology Transfer for Biologics Conference
Gain expert insights on how to create successful partnerships with CMOs and the partnership management skills needed to maintain biologics quality at every step of process transfer.
View the full agenda —Save 15% with code FIERCE |
Resources Sponsored by: AWS and Tableau Inova is using the capabilities of Tableau on AWS to identify biomarkers for personalized treatment intended to improve health outcomes for children. Sponsored by: AWS and Reltio Reltio and IQVIA provide holistic data management solutions for traditional pharma, emerging biotech, and consumer health companies, on AWS. Presented by: AWS and Druva Life Sciences organizations are embracing cloud-based Master Data Management (MDM) to modernize the organization of critical data. Sponsored by: Health Strategies Group The window of market exclusivity continues to narrow dramatically in the global marketplace. Given this demanding environment, your global market access team faces increasing urgency to get the value proposition right at the time of launch. Sponsored by: Patheon, part of Thermo Fisher Scientific “Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market faster. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for these cash-strapped companies whose hopes hinge upon one or two molecules. Read how CDMOs are responding to this pressure. Sponsored by: PharmaCord When was the last time your patient support program perfectly aligned with the patient journey, solving all the critical gaps in positioning your brand for success? Follow the 3-D approach to your solution design, and you will achieve a better outcome for your patients. Sponsored by: WCG Selecting the right sites is the most crucial decision you’ll make in your next clinical trial, and the single most important factor to consider in selecting a site is whether or not it can meet its enrollment goals. Sponsored by: Veeva Industry Research: See new results from one of the industry's largest, global clinical operations surveys. Sponsored by: Veeva Ready to modernize your RIM environment? Secure buy-in with these tips. Sponsored by: Catalent Develop a basic understanding of principles and concepts of bioavailability of oral drugs. Drug Approval, Manufacturing Quality & Regulation 2018 | Online RESI HealthTech Week September 5-7, 2018 | Boston, MA 2018 Latin America Healthcare Compliance Certification Program September 24-27, 2018 | Sao Paulo, Brazil Drug Development Immersion September 26-27, 2018 | West Windsor, NJ FierceBiotech 3rd Drug Development Forum October 1–3, 2018 | Hilton Boston Logan Airport Hotel | Boston, MA Compliance Certification Program at Seton Hall Law October 8-11, 2018 | Newark, NJ BioImmersion: Biotech for the Non-Scientist October 16-18, 2018 | Chicago, IL 2018 BIO Investor Forum October 17-18, 2018 | Westin St. Francis, San Francisco, CA Fierce Innovation Awards: Life Sciences Edition 2018 FierceBiotech Executive Summit: London October 30, 2018 | Royal Society of Medicine Understanding Commercialization Within Biopharma Nov 7-8, 2018 | Boston, MA Drug Development Boot Camp® 2018 – Register Now! November 14-15, 2018 | Boston, MA | Register now and start your pre-Boot Camp preparation Field Service Amsterdam November 27-28, 2018 | NH Collection Amsterdam Grand Hotel Krasnapolsky Drug Development Immersion December 5-6, 2018 | San Diego, CA Understanding Drug Pricing and Reimbursement December 12, 2018 | Boston, MA | 